|
|
Volumn 62, Issue 3, 2015, Pages 975-975
|
|
The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy
a a a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
RITUXIMAB;
SIMEPREVIR PLUS SOFOSBUVIR;
UNCLASSIFIED DRUG;
INTERFERON;
CHRONIC HEPATITIS C;
COST EFFECTIVENESS ANALYSIS;
CRYOGLOBULINEMIA;
CRYOGLOBULINEMIC VASCULITIS;
DISEASE SEVERITY;
HEALTH CARE COST;
HUMAN;
LETTER;
PLASMAPHERESIS;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
VASCULITIS;
AGED;
COHORT ANALYSIS;
COST BENEFIT ANALYSIS;
ECONOMICS;
FEMALE;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HOSPITALIZATION;
IMMUNOLOGY;
IMMUNOTHERAPY;
MALE;
MIDDLE AGED;
MORTALITY;
RETROSPECTIVE STUDY;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
SEVERITY OF ILLNESS INDEX;
SURVIVAL RATE;
VERY ELDERLY;
AGED;
AGED, 80 AND OVER;
COHORT STUDIES;
COST-BENEFIT ANALYSIS;
CRYOGLOBULINEMIA;
FEMALE;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HOSPITALIZATION;
HUMANS;
IMMUNOTHERAPY;
INTERFERONS;
MALE;
MIDDLE AGED;
RETROSPECTIVE STUDIES;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
SEVERITY OF ILLNESS INDEX;
SURVIVAL RATE;
VASCULITIS;
|
|
EID: 84939651756
PISSN: 02709139
EISSN: 15273350
Source Type: Journal
DOI: 10.1002/hep.27600 Document Type: Letter |
|
Times cited : (5)
|
|
References (3)
|
